Citations

Showing 10 of 108104 citations.

Response to Letter to the Editor regarding ‘Characteristics and outcomes of ventricular tachycardia and premature ventricular contractions ablation in patients with prior mitral valve surgery’
Khalil, Fouad , Killu, Ammar M. , Khalil, Fouad

Mayo Clinic

No container title available | April 6, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.164922306.68091730/v1 Get It

We would like to thank the authors for their letter and interest in our manuscript. We appreciate their valuable comments. The authors have raised the following important points: 1. The heterogenicity of our cohort with mitral valve surgery (MVS) 2. Elucidating the characteristics and causes of ventricular arrhythmias (VA) in patients with primary versus secondary mitral disease as well as in those with ischemic versus non-ischemic heart disease 3. The paucity of cardiac magnetic resonance imaging (MRI) as a limitation of the study 4. The need for careful evaluation of patients prior to ablation since most arrhythmias did not originate from the perimitral area.
Reply
Ibrahim, Samar H. , Kamath, Binita M. , Loomes, Kathleen M. , Karpen, Saul J. , Ibrahim, Samar H , Karpen, Saul

Mayo Clinic

Hepatology | April 5, 2022 | Volume: 76 | Issue: 2 | Pages: E47-E47

10.1002/hep.32493 | PMID 35384005 Get It

Automated Identification of Immunocompromised Status in Critically Ill Children
Kandaswamy, Swaminathan , Quincer, Elizabeth , Fernandez, Alfred J., Gonzalez, Mark D. , Lu, Lydia , Kamaleswaran, Rishikesan , Banerjee, Imon , Jaggi, Preeti , Banerjee, Imon , Kamaleswaran, Rishikesan , Orenstein, Evan William

Mayo Clinic

Methods of Information in Medicine | April 5, 2022 | Volume: 61 | Issue: 01/02 | Pages: 046-054

10.1055/a-1817-7208 | PMID 35381616 Get It

Abstract Background Easy identification of immunocompromised hosts (ICHs) would allow for stratification of culture results based on host type. Methods We utilized antimicrobial stewardship program (ASP) team notes written during handshake stewardship rounds in the pediatric intensive care unit (PICU) as the gold standard for host status; clinical notes from the primary team, medication orders during the encounter, problem list, and billing diagnoses documented prior to the ASP documentation were extracted to develop models that predict host status. We calculated performance for three models based on diagnoses/medications, with and without natural language processing from clinical notes. The susceptibility of pathogens causing bacteremia to commonly used empiric antibiotic regimens was then stratified by host status. Results We identified 844 antimicrobial episodes from 666 unique patients; 160 (18.9%) were identified as ICHs. We randomly selected 675 initiations (80%) for model training and 169 initiations (20%) for testing. A rule-based model using diagnoses and medications alone yielded a sensitivity of 0.87 (08.6–0.88), specificity of 0.93 (0.92–0.93), and positive predictive value (PPV) of 0.74 (0.73–0.75). Adding clinical notes into XGBoost model led to improved specificity of 0.98 (0.98–0.98) and PPV of 0.9 (0.88–0.91), but with decreased sensitivity 0.77 (0.76–0.79). There were 77 bacteremia episodes during the study period identified and a host-specific visualization was created. Conclusions An electronic health record–based phenotype based on notes, diagnoses, and medications identifies ICH in the PICU with high specificity.
Transarterial Embolization of Ethmoidal Dural Arteriovenous Fistula: 2-Dimensional Video
Borg, Nicholas , Oushy, Soliman , Brinjikji, Waleed , Oushy, Soliman H , Lanzino, Giuseppe

Mayo Clinic

Operative Neurosurgery | April 5, 2022 | Volume: 22 | Issue: 6 | Pages: e275-e275

10.1227/ons.0000000000000174 | PMID 35383708 Get It

COVID‐19 vaccine in patients with Dravet syndrome: Observations and real‐world experiences
Hood, Veronica , Berg, Anne T. , Knupp, Kelly G. , Koh, Sookyong , Laux, Linda , Meskis, Mary Anne , Ali, Quratulain Zulfiqar , Perry, Μ. Scott , Scheffer, Ingrid E. , Sullivan, Joseph , Zulfiqar-Ali, Quratulain , Perry, Michael Scott , Wirrell, Elaine C , Andrade, Danielle M , Berg, Anne T , Scheffer, Ingrid E , Knupp, Kelly G , Wirrell, Elaine , Andrade, Danielle M.

Mayo Clinic

Epilepsia | April 5, 2022 | Volume: 63 | Issue: 7 | Pages: 1778-1786

10.1111/epi.17250 | PMID 35383912 Get It

AbstractObjectiveVaccination against the SARS‐CoV‐2 virus is a primary tool to combat the COVID‐19 pandemic. However, vaccination is a common seizure trigger in individuals with Dravet syndrome (DS). Information surrounding COVID‐19 vaccine side effects in patients with DS would aid caregivers and providers in decisions for and management of COVID‐19 vaccination.MethodsA survey was emailed to the Dravet Syndrome Foundation's Family Network and posted to the Dravet Parent & Caregiver Support Group on Facebook between May and August 2021. Deidentified information obtained included demographics and vaccination status for individuals with DS. Vaccine type, side effects, preventative measures, and changes in seizure activity following COVID‐19 vaccination were recorded. For unvaccinated individuals, caregivers were asked about intent to vaccinate and reasons for their decision.ResultsOf 278 survey responses, 120 represented vaccinated individuals with DS (median age = 19.5 years), with 50% reporting no side effects from COVID‐19 vaccination. Increased seizures following COVID‐19 vaccination were reported in 16 individuals, but none had status epilepticus. Of the 158 individuals who had not received a COVID‐19 vaccination, 37 were older than 12 years (i.e., eligible at time of study), and only six of these caregivers indicated intent to seek vaccination. The remaining 121 responses were caregivers to children younger than 12 years, 60 of whom indicated they would not seek COVID‐19 vaccination when their child with DS became eligible. Reasons for vaccine hesitancy were fear of increased seizure activity and concerns about vaccine safety.SignificanceThese results indicate COVID‐19 vaccination is well tolerated by individuals with DS. One main reason for vaccine hesitancy was fear of increased seizure activity, which occurred in only 13% of vaccinated individuals, and none had status epilepticus. This study provides critical and reassuring insights for caregivers and health care providers making decisions about the safety of COVID‐19 vaccinations for individuals with DS.
Hepatic Adenomas in Patients 60 and Older Are Enriched for HNF1A Inactivation and Malignant Transformation
Yasir, Saba , Chen, Zongming E., Jain, Dhanpat , Kakar, Sanjay , Wu, Tsung‐Teh, Yeh, Matthew M., Kakar, Sanjay , Torbenson, Michael

Mayo Clinic

American Journal of Surgical Pathology | April 5, 2022 | Volume: 46 | Issue: 6 | Pages: 786-792

10.1097/pas.0000000000001892 | PMID 35383587 Get It

Hepatic adenomas occur most commonly in women between the ages of 20 and 40 years, but rarely they occur in older aged persons, including those 60 years of age or older. This group of adenomas, however, has not been systemically examined. Twenty-six hepatic adenomas in persons 60 years of age or older were studied, along with a control group of 50 hepatic adenomas in persons aged 30 to 39. Hepatic adenomas in persons 60 or more years of age were found in 21 women and 5 men, while the control group had 44 women and 6 men. Subtyping the adenomas in persons 60 years or older showed the following results: 18 HNF1A-inactivated adenomas (69%), 4 inflammatory adenomas (15%), and 4 unclassified adenomas (15%). In contrast, the control group showed a significantly different pattern (P=0.003), with a greater percentage of inflammatory adenomas (28, 56%), fewer HNF1A-inactivated adenomas (8, 16%), and more unclassified adenomas (14, 28%). Atypia and malignant transformation within the hepatic adenomas was studied next. Of the hepatic adenomas in persons age 60 or greater, 3 (12%) showed atypical histologic features, and 6 (23%) had a malignant transformation. In contrast, for hepatic adenomas in the control group, only 4 (8%) adenomas showed atypical histologic features, and 3 (6%) had undergone malignant transformation. In addition, the hepatic adenomas that were atypical or showed early malignant transformation were less likely to have beta-catenin activation in patients over 60 (2/9 cases) compared with those between 30 and 39 years (5/7 cases). Myxoid change and heavy lipofuscin deposition were also more common in adenomas in older aged persons. In conclusion, hepatic adenomas in persons 60 years of age or older are enriched for HNF1A-inactivated adenomas and have a higher frequency of malignant transformation. Malignant transformation, however, is less likely to develop through activation of the beta-catenin pathway.
Comment on: Development of intracranial vasculitis in giant cell arteritis during tocilizumab treatment by Naderi
Koster, Matthew J. , Warrington, Kenneth J. , Lehman, Vance T.

Mayo Clinic

Clinical and Experimental Rheumatology | April 5, 2022 | Volume: 39 | Issue: 2 | Pages: 198-198

10.55563/clinexprheumatol/3k20me | PMID 33686935 Get It

Association of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical Program
Dubinsky, Marla C. , Magro, Fernando , Steinwurz, Flávio , Kinnucan, Jami , Neurath, Markus F. , Kulisek, Nicole, Paulissen, Jerome, Su, Chinyu , León, Darío Ponce de , Kinnucan, Jami A., Regueiro, Miguel , Magro, F , Hudesman, David , Ungaro, Ryan C. , Regueiro, Miguel

Mayo Clinic

Inflammatory Bowel Diseases | April 5, 2022 | Volume: 29 | Issue: 1 | Pages: 51-61

10.1093/ibd/izac061 | PMID 35380664 Get It

Abstract Background Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of ulcerative colitis (UC). These post hoc analyses assessed associations between C-reactive protein (CRP), partial Mayo score (PMS), and efficacy outcomes during tofacitinib induction in UC. Methods Patients received tofacitinib 10 mg twice daily (BID) in an 8-week, phase 2 induction study and 2 identical, 8-week, phase 3 induction studies (OCTAVE Induction 1&2); induction nonresponders (IndNR) received an additional 8 weeks of tofacitinib 10 mg BID in an open-label, long-term extension study. Associations between CRP and PMS, and efficacy outcomes (clinical response, clinical remission, endoscopic improvement, and endoscopic remission) were analyzed using univariate and multivariable logistic regression and receiver operating characteristic curves. Results Changes from baseline in the logarithm of CRP ([log]CRP) and PMS at week 4 were associated with clinical response at week 8 (univariate: per unit, odds ratio [OR], 0.55 [95% confidence interval (CI), 0.48-0.62]; and 0.42 [0.37-0.47], respectively). Among IndNR, change from baseline in PMS at week 8 was associated with clinical response at week 16 (univariate: per unit, OR, 0.59; 95% CI, 0.46-0.75). C-reactive protein at week 4 (area under the curve [AUC] > 0.6) and PMS at weeks 2 and 4 (AUC, > 0.7) generally exhibited predictive value for week 8 efficacy outcomes. Conclusions Patients who achieved clinical response at week 8 had larger decreases in CRP and PMS at week 4 than patients who did not. IndNR who achieved clinical response at week 16 with extended tofacitinib induction had a larger decrease in PMS at week 8 vs those who did not. ClinicalTrials.gov:NCT00787202;NCT01465763;NCT01458951;NCT01470612.
Stereotactic Radiosurgery for Dural Arteriovenous Fistulas: A Systematic Review and Meta-Analysis and International Stereotactic Radiosurgery Society Practice Guidelines
Singh, Raj , Didwania, Prabhanjan, Kotecha, Rupesh , Pollock, Bruce E. , Yomo, Shoji , Sahgal, Arjun , Sheehan, Jason P. , Chen, Ching‐Jen , Fariselli, Laura , Levivier, Marc , Paddick, Ian , Suh, John H.

Mayo Clinic

Neurosurgery | April 5, 2022 | Volume: 91 | Issue: 1 | Pages: 43-58

10.1227/neu.0000000000001953 | PMID 35383682 Get It

BACKGROUND: Dural arteriovenous fistulas (dAVFs) are often treated with stereotactic radiosurgery (SRS) to achieve complete obliteration (CO), prevent future hemorrhages, and ameliorate neurological symptoms. OBJECTIVE: To summarize outcomes after SRS for dAVFs and propose relevant practice recommendations. METHODS: Using a PICOS/PRISMA/MOOSE protocol, we included patients with dAVFs treated with SRS and data for at least one of the outcomes of the study. Relevant outcomes were CO, symptom improvement and cure, and post-SRS hemorrhage or permanent neurological deficits (PNDs). Estimated outcome effect sizes were determined using weighted random-effects meta-analyses using DerSimonian and Laird methods. To assess potential relationships between patient and lesion characteristics and clinical outcomes, mixed-effects weighted regression models were used. RESULTS: Across 21 published studies, we identified 705 patients with 721 dAVFs treated with SRS. The CO rate was 68.6% (95% CI 60.7%-76.5%) with symptom improvement and cure rates of 97.2% (95% CI 93.2%-100%) and 78.8% (95% CI 69.3%-88.2%), respectively. Estimated incidences of post-SRS hemorrhage and PNDs were 1.1% (95% CI 0.6%-1.6%) and 1.3% (95% CI 0.8%-1.8%), respectively. Noncavernous sinus (NCS) dAVFs were associated with lower CO ( P = .03) and symptom cure rates ( P = .001). Higher grade was also associated with lower symptom cure rates ( P = .04), whereas previous embolization was associated with higher symptom cure rates ( P = .01). CONCLUSION: SRS for dAVFs results in CO in the majority of patients with excellent symptom improvement rates with minimal toxicity. Patients with NCS and/or higher-grade dAVFs have poorer symptom cure rates. Combined therapy with embolization and SRS is recommended when feasible for clinically aggressive dAVFs or those refractory to embolization to maximize the likelihood of symptom cure.
Adamantinoma-Like Ewing Sarcoma of the Mandible Evaluated on 18F-FDG PET/CT
Huls, Sean J., Guo, Ray Ruifeng, Binkovitz, Larry A. , Guo, Ruifeng , Guo, Ruifeng , Huls, Sean J. , Broski, Stephen M.

Mayo Clinic

Clinical Nuclear Medicine | April 5, 2022 | Volume: 47 | Issue: 7 | Pages: 635-637

10.1097/rlu.0000000000004195 | PMID 35675138 Get It

Abstract Ewing sarcoma is the second most common primary bone tumor in children. Typical Ewing sarcoma most frequently occurs in long bones and within the pelvis. ALES (adamantinoma-like Ewing sarcoma) is a rare subtype of Ewing sarcoma that is characterized by epithelial differentiation in addition to small round blue cells. Unlike typical Ewing sarcoma, ALES has been described in several cases in the head and neck. Herein, we describe a case of a 9-year-old boy with ALES of the mandible evaluated on 18F-FDG PET/CT with correlative MRI scans.